Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.62−0.90 (-3.27%)
Close on Nov 18, 2026Market cap $2.97BP/E –Yield –
Amylyx Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Amylyx Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2025 was $0. For fiscal 2025 it was $0, down 100.0% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $81.42M | -77.1% |
| FY2023 | Dec 31, 2023 | $355.35M | +1747.2% |
| FY2022 | Dec 31, 2022 | $19.24M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $416.00K | -99.6% |
| Q2 FY2024 | Jun 30, 2024 | -$1.03M | -101.1% |
| Q1 FY2024 | Mar 31, 2024 | $82.70M | +25.0% |
| Q4 FY2023 | Dec 31, 2023 | $99.09M | +419.8% |
| Q3 FY2023 | Sep 30, 2023 | $97.48M | +56243.9% |
| Q2 FY2023 | Jun 30, 2023 | $92.64M | – |
| Q1 FY2023 | Mar 31, 2023 | $66.15M | – |
| Q4 FY2022 | Dec 31, 2022 | $19.06M | – |
| Q3 FY2022 | Sep 30, 2022 | $173.00K | – |
See a number that looks wrong?